Resistance to EGFR-TKIs can also lead to changes in the EGFR genetic profile, histological transformation into SCLC or squamous cell carcinoma, and alterations in the tumor immune microenvironment and programmed death-ligand 1 (PD-L1) expression [50,51]. This evidence concerns the gene EGFR and neoplasm.